168 related articles for article (PubMed ID: 26991123)
41. ATM polymorphisms are associated with risk of radiation-induced pneumonitis.
Zhang L; Yang M; Bi N; Fang M; Sun T; Ji W; Tan W; Zhao L; Yu D; Lin D; Wang L
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1360-8. PubMed ID: 20171797
[TBL] [Abstract][Full Text] [Related]
42. [Genetic variation in SDC2 is associated with the risk of radiation esophagitis in patients with esophageal squamous cell carcinoma receiving radiotherapy].
Zhang M; Zhang W; Du Z; Li H; Huang Y; Yu D; Tan L; Lin D; Xiao Z; Tan W
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):422-6. PubMed ID: 26463144
[TBL] [Abstract][Full Text] [Related]
43. Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy.
Li R; Gu J; Heymach JV; Shu X; Zhao L; Han B; Ye Y; Roth J; Wu X
Carcinogenesis; 2017 Apr; 38(4):419-424. PubMed ID: 28186269
[TBL] [Abstract][Full Text] [Related]
44. Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer. Feasibility and toxicity study.
Catalano G; Jereczek-Fossa BA; De Pas T; Leon ME; Cattani F; Spaggiari L; Veronesi G; de Braud F; Orecchia R
Strahlenther Onkol; 2005 Jun; 181(6):363-71. PubMed ID: 15925978
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.
Geng JQ; Wang XC; Li LF; Zhao J; Wu S; Yu GP; Zhu KJ
Tumour Biol; 2016 Feb; 37(2):2257-65. PubMed ID: 26358254
[TBL] [Abstract][Full Text] [Related]
46. Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer.
He K; Zhang S; Pang J; Yin JC; Mu D; Wang J; Ge H; Ma J; Yang Z; Zheng X; Dong L; Zhang J; Chang P; Li L; Tang S; Bao H; Wu X; Wang X; Shao Y; Yu J; Yuan S
Front Oncol; 2022; 12():928605. PubMed ID: 35912186
[TBL] [Abstract][Full Text] [Related]
47. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
48. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
49. A NEIL1 single nucleotide polymorphism (rs4462560) predicts the risk of radiation-induced toxicities in esophageal cancer patients treated with definitive radiotherapy.
Chen Y; Zhu M; Zhang Z; Jiang G; Fu X; Fan M; Sun M; Wei Q; Zhao K
Cancer; 2013 Dec; 119(23):4205-11. PubMed ID: 24022861
[TBL] [Abstract][Full Text] [Related]
50. Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.
Liu B; Tang Y; Yi M; Liu Q; Xiong H; Hu G; Yuan X
Cancer Med; 2017 Mar; 6(3):681-688. PubMed ID: 28211612
[TBL] [Abstract][Full Text] [Related]
51. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy.
Song CH; Pyo H; Moon SH; Kim TH; Kim DW; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):651-8. PubMed ID: 20207499
[TBL] [Abstract][Full Text] [Related]
52. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
53. Association of single nucleotide polymorphisms at HSPB1 rs7459185 and TGFB1 rs11466353 with radiation esophagitis in lung cancer.
Delgado BD; Enguix-Riego MV; Fernández de Bobadilla JC; Herrero Rivera D; Nieto-Guerrero Gómez JM; Praena-Fernández JM; Rivin Del Campo E; Ortiz Gordillo MJ; Fernandez Fernandez MDC; Lopez Guerra JL
Radiother Oncol; 2019 Jun; 135():161-169. PubMed ID: 31015163
[TBL] [Abstract][Full Text] [Related]
54. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
[TBL] [Abstract][Full Text] [Related]
55. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
[TBL] [Abstract][Full Text] [Related]
56. Variant SNPs at the microRNA complementary site in the B7‑H1 3'‑untranslated region increase the risk of non‑small cell lung cancer.
Du W; Zhu J; Chen Y; Zeng Y; Shen D; Zhang N; Ning W; Liu Z; Huang JA
Mol Med Rep; 2017 Sep; 16(3):2682-2690. PubMed ID: 28677815
[TBL] [Abstract][Full Text] [Related]
57. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients.
Pu X; Roth JA; Hildebrandt MA; Ye Y; Wei H; Minna JD; Lippman SM; Wu X
Cancer Res; 2013 Mar; 73(6):1867-75. PubMed ID: 23378343
[TBL] [Abstract][Full Text] [Related]
59. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
60. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
